About This Information
This section provides supporting information for the Enjaymo (sutimlimab) Dosing Calculator. The calculator is a clinical support tool for U.S. Healthcare Professionals to determine the appropriate weight-based dose and initial infusion schedule for adult patients with cold agglutinin disease (CAD), in accordance with the U.S. Prescribing Information.
Calculator Outputs
Upon entering the required patient data, the calculator will generate the following information:
- Calculated Dose: A specific dose of either 6,500 mg or 7,500 mg based on the patient’s body weight.
- Initial Dosing Schedule: A list of the first six administration dates, beginning with the specified treatment start date and following the approved regimen (weekly for two weeks, then bi-weekly).
How to Use the Calculator
To ensure accurate results, follow these steps:
- Enter Patient Weight: Input the patient’s current body weight. Select the appropriate unit of measurement (kg or lbs).
- Select Start Date: Choose the intended date for the first infusion using the date picker.
- Acknowledge Disclaimer: Read and check the box to confirm you understand that the tool is for informational purposes and does not replace clinical judgment.
- Calculate: Click the “Calculate Dose & Schedule” button to view the results. The “Reset” button will clear all fields.
Dosing Overview
Enjaymo is administered as an intravenous infusion. The dose is determined by the patient’s body weight.
- For patients weighing less than 75 kg (165 lbs), the recommended dose is 6,500 mg.
- For patients weighing 75 kg or more, the recommended dose is 7,500 mg.
The administration schedule consists of a weekly infusion for the first two weeks (Day 0 and Day 7), followed by an infusion every two weeks thereafter.
Switching Therapy
The Prescribing Information does not provide specific guidance on switching to Enjaymo from other therapies for cold agglutinin disease. Treatment decisions regarding switching should be based on a healthcare provider’s clinical judgment and the individual patient’s clinical status.
Missed Dose
If a dose of Enjaymo is missed, it should be administered as soon as possible. The treatment schedule should then be adjusted to maintain the recommended dosing interval. For detailed instructions on managing deviations from the schedule, always consult the most current full Prescribing Information.
Safety Alerts & Administration
Vaccinations for Encapsulated Bacteria
Enjaymo increases the risk of serious and life-threatening infections caused by encapsulated bacteria. To mitigate this risk, patients must be vaccinated against Streptococcus pneumoniae, Neisseria meningitidis (serogroups A, C, W, Y, and B), and Haemophilus influenzae type B at least 2 weeks prior to receiving the first dose, in accordance with current ACIP guidelines. If urgent treatment is required, administer vaccines as soon as possible.
Premedication
To reduce the risk of infusion-related reactions, it is recommended to administer premedications (e.g., antihistamine, corticosteroid, antipyretic) approximately 60 minutes prior to each Enjaymo infusion.
Frequently Asked Questions
What is the source of the dosing information in the calculator?
The calculator’s logic is based on the FDA-approved U.S. Prescribing Information for Enjaymo (sutimlimab-jome) dated February 2022.
Why are there two different doses (6,500 mg and 7,500 mg)?
The dose is weight-based. The 75 kg threshold determines which of the two standard doses is appropriate for the patient.
What should I do if a patient’s weight changes during treatment?
The Prescribing Information does not specify a need for dose adjustment based on weight changes after initiating therapy. Continue with the initially determined dose unless clinical judgment warrants re-evaluation. Always refer to the full PI.
Does the calculator provide the maintenance dosing schedule?
The calculator generates the initial 9-week treatment schedule. After this period, dosing continues on an every-two-weeks basis as per the Prescribing Information.
Can this calculator be used for pediatric patients?
No. The safety and effectiveness of Enjaymo have not been established in pediatric patients. This tool is intended for adult patients only.
What should I do if the calculator displays an error message?
An error typically occurs if a required field is incomplete. Ensure you have entered a valid, positive number for weight, selected a start date, and checked the disclaimer acknowledgement box.
Does this tool replace the official Prescribing Information?
No. This tool is for informational and convenience purposes only. It is not a substitute for the full Prescribing Information or a healthcare provider’s clinical judgment. All treatment decisions must be made in the context of the patient’s full clinical picture.
How is Enjaymo administered?
Enjaymo is administered via intravenous (IV) infusion by a healthcare professional.
References
- ENJAYMO® (sutimlimab-jome) Prescribing Information. Sanofi-Aventis U.S. LLC; February 2022.
- Enjaymo HCP Website. Sanofi.
- Recommended Adult Immunization Schedule for ages 19 years or older, United States. Centers for Disease Control and Prevention.
- Röth A, Berentsen S, Barcellini W, et al. Sutimlimab in Cold Agglutinin Disease. N Engl J Med. 2021;384(14):1323-1334.
I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.
Mail- Sachin@pharmacyfreak.com